Study shows promise in repairing damaged myelin

A scientific breakthrough provides new hope for millions of people
living with multiple sclerosis. Researchers at OHSU have developed a
compound that stimulates repair of the protective sheath that covers
nerve cells in the brain and spinal cord.

The discovery, involving mice genetically engineered to mimic multiple sclerosis, published today in the journal JCI Insight.

MS is a chronic condition that affects an estimated 2.3 million
people worldwide. In MS, the sheath covering nerve fibers in the brain
and spinal cord becomes damaged, slowing or blocking electrical signals
from reaching the eyes, muscles and other parts of the body. This sheath
is called myelin. Although myelin can regrow through exposure to
thyroid hormones, researchers have not pursued thyroid hormone therapies
due to unacceptable side effects.

Although several treatments and medications alleviate the symptoms of MS, there is no cure.

“There are no drugs available today that will re-myelinate the
de-myelinated axons and nerve fibers, and ours does that,” said senior
author Tom Scanlan, Ph.D., professor of physiology and pharmacology in the OHSU School of Medicine.

Co-author Dennis Bourdette, M.D., chair of neurology
in the OHSU School of Medicine and director of the OHSU Multiple
Sclerosis Center, said he expects it will be a few years before the
compound advances to the stage of a clinical trial involving people. Yet
the discovery provides fresh hope for patients in Oregon and beyond.

“It could have a significant impact on patients debilitated by MS,” Bourdette said.

The discovery reported, if ultimately proven in clinical trials
involving people, appears to accomplish two important goals:

  • Myelin repair with minimal side effects: The study
    demonstrated that the compound – known as sobetirome – promotes
    remylenation without the severe side effects of thyroid hormone therapy.
    Thyroid hormone therapy has not been tried in people because chronic
    elevated exposure known as hyperthyroidism harms the heart, bone, and
    skeletal muscle.
  • Efficient delivery: Researchers developed a new
    derivative of sobetirome (Sob-AM2) that penetrates the blood brain
    barrier, enabling a tenfold increase in infiltration to the central
    nervous system.

“We’re taking advantage of the endogenous ability of thyroid hormone
to repair myelin without the side effects,” said lead author Meredith Hartley, Ph.D., an OHSU postdoctoral researcher in physiology and pharmacology.

Co-authors credited the breakthrough to a collaboration that involved
scientists and physicians with expertise ranging across neurology,
genetics, advanced imaging, physiology and pharmacology.

Potential as a ‘total game-changer’

One patient said the research could be a “total game-changer” for people with MS.

Laura Wieden, 48, has lived with multiple sclerosis
since being diagnosed in 1995. The daughter of Portland advertising
executive Dan Wieden, she is the namesake and board member of the Laura
Fund for Innovation in Multiple Sclerosis, which funded much of the
research involved in the study published today.

“I am really optimistic,” Wieden said. “I hope that this will be
literally a missing link that could just change the lives of people with
MS.”

Scanlan originally developed sobetirome as a synthetic molecule more
than two decades ago, initially with an eye toward using it to lower
cholesterol. In recent years, Scanlan’s lab adapted it as a promising treatment for a rare metabolic disease called adrenoleukodystrophy, or ALD.

Six years ago, Bourdette suggested trying the compound to repair myelin in MS.

Supported by funding provided through the Laura Fund and the National
Multiple Sclerosis Society, the team turned to Ben Emery, Ph.D., an
associate professor of neurology in the OHSU School of Medicine. Emery,
an expert who previously established his own lab in Australia focused on
the molecular basis of myelination, genetically engineered a mouse
model to test the treatment.

A ‘Trojan horse’

With promising early results, researchers wanted to see if they could
increase the amount of sobetirome that penetrated into the central
nervous system.

They did so through a clever trick of chemistry known as a prodrug strategy.

Scientists added a chemical tag to the original sobetirome molecule,
creating an inert compound called Sob-AM2. The tag’s main purpose is to
eliminate a negative charge that prevents sobetirome from efficiently
penetrating the blood-brain barrier. Once Sob-AM2 slips past the barrier
and reaches the brain, it encounters a particular type of brain enzyme
that cleaves the tag and converts Sob-AM2 back into sobetirome.

“It’s a Trojan horse type of thing,” Scanlan said.

Researchers found that the treatment in mice not only triggered
myelin repair, but they also measured substantial motor improvements in
mice treated with the compound.

“The mouse showed close to a full recovery,” Scanlan said.

Scientists say they are confident that the compound will translate
from mice to people. To that end, OHSU has licensed the technology to
Llama Therapeutics Inc., a biotechnology company in San Carlos,
California. Llama is working to advance these molecules toward human
clinical trials in MS and other diseases.

Bourdette said even though it may not help his patients today, he’s
optimistic the discovery eventually will move from the lab into the
clinic.

“Right now, what it means is hope,” he said.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here